Oncotelic Therapeutics, Inc.: CBO presents PLA research at DDSS

What happened Oncotelic Therapeutics, Inc. reported that on Oct 22, 2026 Saran Saund, chief business officer, presented at the 22nd Drug Discovery Strategic Summit in Millbrae, California. The presentation, titled “Partitioning 29 Million PubMed Abstracts by Disease Turns a Literature Review into a Discovery. A Four-Gene mTOR Signature Defining a Candidate Hepatocellular Carcinoma Population.”, described the company’s Partitioned Literature Aggregation (PLA) framework and its application in liver cancer research, including identification of a 4-gene mTOR-related signature associated with patient outcomes. The presentation is included as an exhibit to the Current Report on Form 8-K.

Key details

• Presenter and date: Saran Saund, chief business officer, presented on Oct 22, 2026 at the 22nd Drug Discovery Strategic Summit.
• Literature scope and finding: PLA partitioned 29,000,000 PubMed abstracts and the analysis, combined with gene-expression and survival analyses, identified a 4-gene mTOR-related signature linked to hepatocellular carcinoma patient outcomes.
• planned expansion: the presentation outlined plans to expand PLA using autonomous AI agents and a planned research environment targeting 100 billion (100,000,000,000) protein-related vectors to support drug discovery across multiple disease areas.
• filing treatment: the Form 8-K states the information in Section 8.01, including the exhibit presentation, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor be deemed incorporated by reference except as expressly set forth.

Why it may matter This report was made under Item 8.01 (Other events), which covers the furnished presentation describing the PLA framework, the 4-gene mTOR signature finding in liver cancer, and planned PLA expansions. A filing does not show why the insider traded or why the company acted.